Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D L Porter

Showing results (31-40 of 55) with videos related to

Pageof 6
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
Graft-versus-tumor induction with donor leukocyte infusions as primary therapy for patients with malignanciesD L Porter, J M Connors, V M Van Deerlin, et al.
Annals of Hematology|August 20, 2002
Nonmyeloablative allogeneic stem cell transplantation for refractory Hodgkin's lymphoma complicated by interleukin-2 responsive progressive multifocal leukoencephalopathyR J Buckanovich, G Liu, C Stricker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2000
Phase I trial of TALL-104 cells in patients with refractory metastatic breast cancerS Visonneau, A Cesano, D L Porter, et al.
Bone Marrow Transplantation|December 23, 2015
Higher tacrolimus concentrations early after transplant reduce the risk of acute GvHD in reduced-intensity allogeneic stem cell transplantationA Ganetsky, A Shah, T A Miano, et al.
Bone Marrow Transplantation|July 10, 2002
Gemtuzumab ozogamicin (Mylotarg) monotherapy for relapsed AML after hematopoietic stem cell transplant: efficacy and incidence of hepatic veno-occlusive diseaseA D Cohen, S M Luger, C Sickles, et al.
Gynecologic Oncology|January 27, 1998
Cycles of dose-intensive chemotherapy with peripheral stem cell support in persistent or recurrent platinum-sensitive ovarian cancerM A Morgan, E A Stadtmauer, S M Luger, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|January 12, 2011
Reduction of immunosuppression as initial therapy for posttransplantation lymphoproliferative disorder(★)R Reshef, S Vardhanabhuti, M R Luskin, et al.
Leukemia|February 28, 2015
CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemiaS S Kenderian, M Ruella, O Shestova, et al.
Bone Marrow Transplantation|October 25, 2011
Allogeneic hematopoietic SCT for primary cutaneous T cell lymphomasV R Paralkar, S D Nasta, K Morrissey, et al.
Transplantation|May 26, 2001
Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patientsD E Tsai, C L Hardy, J E Tomaszewski, et al.
Pageof 6

Showing results (31-40 of 55) with videos related to

Sort By:
Pageof 6
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
Graft-versus-tumor induction with donor leukocyte infusions as primary therapy for patients with malignanciesD L Porter, J M Connors, V M Van Deerlin, et al.
Annals of Hematology|August 20, 2002
Nonmyeloablative allogeneic stem cell transplantation for refractory Hodgkin's lymphoma complicated by interleukin-2 responsive progressive multifocal leukoencephalopathyR J Buckanovich, G Liu, C Stricker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2000
Phase I trial of TALL-104 cells in patients with refractory metastatic breast cancerS Visonneau, A Cesano, D L Porter, et al.
Bone Marrow Transplantation|December 23, 2015
Higher tacrolimus concentrations early after transplant reduce the risk of acute GvHD in reduced-intensity allogeneic stem cell transplantationA Ganetsky, A Shah, T A Miano, et al.
Bone Marrow Transplantation|July 10, 2002
Gemtuzumab ozogamicin (Mylotarg) monotherapy for relapsed AML after hematopoietic stem cell transplant: efficacy and incidence of hepatic veno-occlusive diseaseA D Cohen, S M Luger, C Sickles, et al.
Gynecologic Oncology|January 27, 1998
Cycles of dose-intensive chemotherapy with peripheral stem cell support in persistent or recurrent platinum-sensitive ovarian cancerM A Morgan, E A Stadtmauer, S M Luger, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|January 12, 2011
Reduction of immunosuppression as initial therapy for posttransplantation lymphoproliferative disorder(★)R Reshef, S Vardhanabhuti, M R Luskin, et al.
Leukemia|February 28, 2015
CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemiaS S Kenderian, M Ruella, O Shestova, et al.
Bone Marrow Transplantation|October 25, 2011
Allogeneic hematopoietic SCT for primary cutaneous T cell lymphomasV R Paralkar, S D Nasta, K Morrissey, et al.
Transplantation|May 26, 2001
Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patientsD E Tsai, C L Hardy, J E Tomaszewski, et al.
Pageof 6